<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>158-DAPOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo or syncope type</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>158-DAPOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo and fainting type</DESCRIPTION>
<SEVERITY>Nor recommended</SEVERITY>
<COMMENT>-with the type 5 phosphodiesterase inhibitors </COMMENT>
</INTERACTION>
</INTERACTIONS>
